Straits Times Index
3,439.88 +24.37 (+0.71%) S&P 500
5,537.02 +28.01 (+0.51%) Dow
39,308.00 -23.90 (-0.06%) Nasdaq
18,188.30 +159.54 (+0.88%) Bitcoin USD
57,175.22 -3,169.06 (-5.25%) CMC Crypto 200
1,200.78 -60.40 (-4.79%)
Edwards Lifesciences Corp (EWL.BE)
| Previous close | 84.47 |
| Open | 84.11 |
| Bid | 85.10 x 0 |
| Ask | 85.63 x 0 |
| Day's range | 84.11 - 84.11 |
| 52-week range | 58.34 - 88.06 |
| Volume | |
| Avg. volume | 1 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Five-Year Data Show Excellent Outcomes for Female and Small Annulus Patients With Edwards TAVR
NEW YORK, June 05, 2024--Edwards Lifesciences (NYSE: EW) today announced the results from an analysis of data from the PARTNER Trials examining outcomes of transcatheter aortic valve replacement (TAVR) patients with a small annulus. Through five-year follow up of more than 1,300 low and intermediate risk SAPIEN 3 valve patients there were excellent clinical outcomes and valve durability irrespective of the patient’s annulus size or sex. These data were presented during the late-breaking clinical
- PR Newswire
BD to Acquire Edwards Lifesciences' Critical Care Product Group for $4.2 Billion to Expand Smart Connected Care Solutions and Become an Advanced Monitoring Technology Leader
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Edwards Lifesciences (NYSE: EW), today announced a definitive agreement under which BD will acquire Edwards' Critical Care product group ("Critical Care"), a global leader in advanced monitoring solutions, for $4.2 billion in cash, unlocking new value creation opportunities and enhancing BD's portfolio of smart connected care solutions.
- Business Wire
Edwards Lifesciences to Sell Critical Care to BD
IRVINE, CA, June 03, 2024--Edwards Lifesciences (NYSE: EW) today announced it has entered into a definitive agreement to sell its Critical Care product group to BD (Becton, Dickinson and Company) (NYSE: BDX), in an all-cash transaction valued at $4.2 billion. With this agreement, Edwards is no longer pursuing the previously announced spin-off of Critical Care.
